Drugs / BNT162b2 bivalent (wildtype and Omicron BA.1)
BNT162b2 bivalent (wildtype and Omicron BA.1)
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05289037 | Mar 2022 → Nov 2023 | COVID-19 | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BNT162b2 bivalent (wildtype and Omicron BA.1) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05289037 ↗ |
| Modality | Messenger RNA (mRNA) | “Contains mRNA that encodes for the prefusion stabilized S protein of the Omicron BA.1 variant SARS-CoV-2 strain and the ancestral strain of SARS-CoV-2.” NCT05289037 ↗ |
| Route | Intramuscular | “administered through intramuscular injection” NCT05289037 ↗ |